Biotech
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
2024-02-19 09:00
3052
SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...
Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis
2024-02-15 16:05
1713
LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
2024-02-15 11:37
1304
▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...
YS Biopharma Announces Appointment of New Directors
2024-02-14 20:50
3396
GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
2024-02-14 08:07
3594
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...
Delta Thailand Wins Prime Minister's Best Industry Award and MIND Ambassador Award 2023 for Outstanding Contributions
2024-02-13 16:37
1849
BANGKOK, Feb. 13, 2024 /PRNewswire/ -- Delta Electronics (Thailand) PCL. received the Prime Minister's Best Industry Award 2023, which is the highest honor above all other Prime Minister's Industry Award categories given to only one select company each year. In addition, Delta received the MIND A...
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
2024-02-13 03:26
3739
VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...
UFC WORLD CHAMPION JON JONES, LIFECYKEL LABS, CANTERBURY-BANKSTOWN BULLDOGS AND BETTER BREATHING DEVICES HOST ELITE PERFORMANCE/TRAINING DAY
2024-02-09 18:09
3033
SYDNEY, Feb. 9, 2024 /PRNewswire/ -- Jon Jones, UFC world champion and arguably the best MMA fighter to have ever existed is touringAustralia and has teamed up with Lifecykel Labs to host and facilitate a best-in-class performance training day which was held at the Canterbury-Bankstown Bulldogs h...
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
2024-02-09 11:22
2237
BENGALURU, India, Feb. 9, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, ...
Cathay Biotech and 3P.COM Signed Joint Venture Agreement to Propel Sustainable Composite Innovations
2024-02-08 23:00
1615
China's Cathay Biotech Inc. and South Korea's 3P.COM Co. Limited signed an agreement to establish a joint venture, targeting the development of bio-based polyamide thermoplastic composites. SHANGHAI, Feb. 8, 2024 /PRNewswire/ -- Cathay Biotech Inc. ("Cathay") and 3P.COM Co. Limited ("3P.COM") s...
MGI Named a Finalist in the 2024 Edison Awards™ for Innovative DNBSEQ-T20x2* Gene Sequencer
2024-02-08 21:00
1458
SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech
Tianlong's New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024
2024-02-08 21:00
2703
DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- The 4-day Medlab Middle East 2024 at the Dubai World Trade Center came to an end successfully onFebruary 8. MedLab is the largest exhibition of medical equipment in theMiddle East region, attracting visitors worldwide to experience the academic atmosphere ...
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
2024-02-07 19:00
1267
* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech * Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reduc...
NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy
2024-02-05 21:00
1409
WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period...
Innovent Announces Retirement of CFO and Appointment of New CFO
2024-02-05 16:45
2411
ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other ...
Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery
2024-02-05 09:53
1484
HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robot...
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
2024-02-05 08:00
1223
* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...
Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business
2024-02-03 08:00
2101
SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
2024-02-02 22:00
1492
* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
2024-02-02 21:30
1962
YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00Most Read
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3322
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3069